The CFPB recently denied a lender’s request to set aside or modify a civil investigative demand (CID) issued in January related to its short-term and small-dollar lending practices. The lender’s ...
Researchers from Circle Pharma Inc. have presented preclinical data for CID-078, a novel orally bioavailable cyclin A/B Rxl macrocycle being developed for the treatment of patients with lung cancer.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, a clinical-stage biopharmaceutical company advancing macrocycle therapeutics for difficult-to-treat cancers, today announced that the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback